Advancements in Migraine Therapies: Opportunities for Pharmacists to Intervene


Only one-third of individuals who are eligible for migraine preventive regimens actually receive them, and over 75% of these individuals become noncompliant due to adverse effects and lack of efficacy. Recently, calcitonin gene-related peptide (CGRP) antagonists were approved for preventive treatment against migraines, and they have been proven to be more effective and safer than previous therapies. Pharmacists have an important role in educating patients on medication and proper administration along with encouraging patient compliance in order for the patient to receive optimal therapeutic effects.

Speakers: Nikki Hahn, PharmD, BCACP, Kaiser Permanente of Colorado; Paul Mathew, MD, FAAN, FAHS, Harvard Medical School

Register today at .


Pharmacist Learning Objectives

At the completion of this activity, participants will be able to:

  1. Examine the clinical features associated with migraines.
  2. Explain safety and efficacy of newly approved agents for migraines.
  3. Identity opportunities for pharmacists to intervene optimize migraine treatment and prevent adverse drug events.




Presented by Pharmacy Times Continuing Education and supported by an independent educational grant from Eli Lilly and Company and Amgen.

Learning Level: Level 2
Track: Satellite Symposia
Session Time Slot(s): 
Saturday, March 23
6:00 AM - 8:00 AM
Grand Hyatt Seattle - Princessa Ballroom
ACPE Pharmacist: 0290-0000-19-012-L01-P
CEUs Pharmacist: 0.15
Activity Type: